Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

share, compared to a net loss of $42.2 million, or $0.96 per share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $4.4 million decrease in research and development expenses related to KRX-0401, and a $21.1 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with JT/Torii ($18.0 million), as discussed above, and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made significant progress over the last few months. We presented important Phase 2 data on both our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time Keryx will be in the compelling position of having two Phase 3 compounds." Mr. Bentsur added, "I am excited by the opportunity to transform Keryx into a late-stage development company and maximize shareholder value. On behalf of the entire Keryx team, I want to thank all of our shareholders for their continued support."

On Thursday, August 6, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results and a business outlook for the remainder of 2009.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract ... will host a complimentary webinar on “Cleaning Validation: Science, ... 4, 2013 at 11 a.m. Eastern Standard Time. ... regulations for cleaning validation. Many companies have incorporated ... evaluation of risk. Some companies have chosen to ...
(Date:5/23/2013)... The maker community is a contemporary group ... focus on learning practical skills while applying them creatively ... their ideas to life via crowdfunding. A subgroup within ... projects using biology. Glowing Plant has worked for months ... glow with bioluminescence genes, and has now pursued crowdfunding ...
(Date:5/23/2013)...  Saddleback Memorial Medical Center in Laguna ... on the West Coast to perform a hysterectomy using ... women with a state-of-the-art, minimally invasive approach to gynecological ... , M.D., a highly regarded Orange County ... minimally invasive surgery at Saddleback Memorial, led the surgical ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 On April ... trips to supermarkets to search for the growing antibiotic ... aisles. Results from a year long study were released ... in foods, specifically meats, over previous years. For those ... the growth of antibiotic resistant bacteria in food, may ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... , FALLS CHURCH, Va., Aug. 20 ... information technology to the federal government, announced today that ... Defense (DoD) Military Health Services for enhancements to the ... Affairs (VA) clinician access to DoD information on a ...
... ... challenges related to the synthesis of peptide libraries and will include the synthesis of ... for biological screening. , ... Columbia, MD (PRWEB) August 20, 2009 -- METTLER TOLEDO will sponsor a free ...
... , , BELLE MEAD, ... in Northern New Jersey will streamline and improve the quality of ... http://www.hi-consult i ng.net ), a leader in ... firm was selected to oversee all aspects of practice management and ...
Cached Biology Technology:Evolvent Awarded Health Information Exchange Contract 2Synthesis and Purification of Peptide Libraries -- Innovative Approaches 2New Jersey Surgery Centers Pick Health Informatics Consulting to Implement Patient Electronic Health Record Systems 2
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
(Date:5/22/2013)... May 22, 2013 U.S. Forest Service scientists are ... with funding from the TKF Foundation, will examine how ... and individuals recover from tragedy. , The TKF Foundation ... six projects selected for grant funding. In addition to ... spaces in recovery and resiliency, the 3-year, $585,000 grant ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... PHILADELPHIA, PA − A new study from the Infant ... for Autism Research at the Children,s Hospital of Philadelphia ... age 6 months in high-risk infants who later develop ... autism. "It,s a tremendously exciting finding," said Sarah ...
... Ontario The Deepwater Horizon oil spill in the Gulf of Mexico ... U.S. Gulf fisheries. A new study published in the Canadian ... that over 7 years this oil spill could have a $US8.7 ... includes losses in revenue, profit, and wages, and close to 22 ...
... senior scientist and director of the Marine Biological Laboratory ... Antarctic Program Blue Ribbon Panel. The 12-member panel, ... the White House Office of Science and Technology Policy ... is tasked with examining the status and capabilities of ...
Cached Biology News:New autism research reveals brain differences at 6 months in infants who develop autism 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
RORgamma (S-14)...
... Glutathion-S-Transferase-pi EIA Principle: Glutathion-S-transferases ... which are involved in the detoxification ... 5 subgroups: Alpha, Mu, Pi, Teta ... their physiochemical, immunological, enzymatic and s ...
... Sophions newly introduced QPatch HT is taking automated ... powerful level. With its ability to generate thousands ... is enabling new screening paradigms in ion channel ... with the same high quality afforded by conventional ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
Biology Products: